In the latest trading session, Astrazeneca (AZN) closed at $75.57, marking a +1.79% move from the previous day.

The AstraZeneca PLC ADR AZN rose 1.79% to $75.57 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...

AstraZeneca PLC (NASDAQ:AZN – Get Free Report) has been given an average recommendation of “Buy” by the ten ratings firms that are currently covering the company, Marketbeat.com reports. One equities ...

The AstraZeneca PLC ADR AZN slid 2.30% to $74.24 Tuesday, on what proved to be an all-around dismal trading session for the ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

The latest trading session saw Astrazeneca (AZN) ending at $77.47, denoting a -0.63% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily loss of 1.78%.

AstraZeneca boasts a remarkably healthy drug portfolio and a pipeline of promising drugs in clinical development. Read why ...

Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.

George Soros's 13F portfolio value decreased to $6.65B with 190 positions. Click here for a detailed analysis.

Hopeful the drug will be approved for treating nasal polyps, he said: "All being well, if the price is right ... so we'll have to wait and see." AstraZeneca closed flat at 12,018.00 pence per share on ...

Astrazeneca (AZN) ended the recent trading session at $76.21, demonstrating a +0.74% swing from the preceding day's closing price. The stock's change was less than the S&P 500's daily gain of 1.59%.

In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) stands against the other best vaccine stocks to buy now. On February 24, CNBC reported that President Trump ...